STERIS (NYSE:STE) Announces Quarterly Earnings Results

STERIS (NYSE:STE) released its earnings results on Wednesday. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53, FiscalAI reports. STERIS had a return on equity of 14.49% and a net margin of 12.15%.The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.48 billion. During the same quarter last year, the business posted $2.32 EPS. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. STERIS updated its FY 2026 guidance to 10.150-10.300 EPS.

STERIS Stock Performance

STE traded up $2.68 during midday trading on Friday, reaching $246.49. The company had a trading volume of 207,074 shares, compared to its average volume of 642,563. The business has a 50-day moving average of $258.70 and a two-hundred day moving average of $249.50. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27. STERIS has a 1 year low of $204.90 and a 1 year high of $269.44. The company has a market cap of $24.19 billion, a P/E ratio of 34.38 and a beta of 1.03.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s payout ratio is currently 36.21%.

Insider Activity

In related news, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the completion of the transaction, the vice president directly owned 33,669 shares in the company, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Renato Tamaro sold 5,036 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president owned 5,695 shares in the company, valued at approximately $1,466,747.25. The trade was a 46.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,044 shares of company stock valued at $6,586,218 in the last ninety days. Corporate insiders own 1.07% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of STE. Jones Financial Companies Lllp increased its stake in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock worth $251,000 after buying an additional 349 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock worth $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC grew its position in shares of STERIS by 16.1% during the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 319 shares in the last quarter. Woodline Partners LP raised its stake in STERIS by 40.0% during the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after purchasing an additional 2,372 shares during the period. Finally, Jane Street Group LLC lifted its holdings in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after purchasing an additional 5,803 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.